DURECT Sells ALZET Osmotic Pumps for $17.5M, Pays Off Loan Obligations
DURECT Sells ALZET Osmotic Pumps for $17.5M, Pays Off Loan Obligations
DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET line of osmotic pumps to Lafayette Instrument Co. (LIC), a portfolio company of Branford Castle Partners II, L.P., a North-American focused private equity firm.
Durect Corporation（纳斯达克股票代码：DRRX）是一家处于后期阶段的生物制药公司，该公司率先开发表观遗传学疗法，以改变急性器官损伤等严重和危及生命的疾病的治疗方法。该公司今天宣布将其AlZet系列渗透泵出售给拉斐特仪器有限公司。(LIC)，一家专注于北美的私募股权公司Branford Castle Partners II, L.P. 旗下的投资组合公司。
) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer." alt="DURECT Corporation () is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer.">
）是一家处于后期阶段的生物制药公司，率先开发针对失调的DNA甲基化的表观遗传学疗法，以改变包括急性器官损伤和癌症在内的严重和危及生命的疾病的治疗方法。” alt= “Durect Corporation () 是一家后期生物制药公司，率先开发针对失调的DNA甲基化的表观遗传学疗法，以改变包括急性器官损伤和癌症在内的严重和危及生命的疾病的治疗。“>
Under the terms of the agreement, LIC paid DURECT $17.5 million in exchange for certain assets and liabilities associated with the ALZET product line. Simultaneous with this transaction, DURECT has paid off all remaining obligations under the term loan agreement with Oxford Finance LLC.
根据协议条款，LIC向Durect支付了1750万美元，以换取与AlZet产品系列相关的某些资产和负债。在这笔交易的同时，Durect还清了与牛津金融有限责任公司签订的定期贷款协议下的所有剩余债务。
